Insider Trading Arrangements

3 Months Ended

Mar. 31, 2025

shares

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

During the quarter ended March 31, 2025, the Rule 10b5-1 trading arrangement adopted by Darin Weber, Chief Regulatory Officer was modified on January 15, 2025 and is intended to satisfy the affirmative defense of Rule 10b5-1(c). The Rule 10b5-1 trading arrangement provides for the sale of up to an aggregate of 103,480 shares of our Class A ordinary shares until December 17, 2025.

On May 8, 2025, ProKidney Corp. (the “Company”), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC, entered into a purchase and sale agreement with Williams Development Group, LLC (the “Agreement”) to sell the Company’s

real property located in Greensboro, North Carolina for approximately $19.5 million in cash. The Agreement contains customary representations and closing conditions for a transaction of this type.

Name

Darin Weber

Title

Chief Regulatory Officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

January 15, 2025

Aggregate Available

103,480